More than half of Ozempic users prescribed the drug for obesity alone are stopping or reducing their doses within a year, driven by a collision of gastrointestinal side effects, steep out-of-pocket ...

Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript March 5, 2026 Altimmune, Inc. misses on earnings expectations. Reported EPS is $-0.27191 EPS, expectations were $-0.25. Operator: Good ...

Ritu Baral TD Cowen, Research Division. Thank you, everyone, for joining us for the Praxis fireside chat here at the TD Cowen Healthcare Conference. I'm covering analyst Ritu Bara ...